Latest News

KRSNAA

Krsnaa Diagnostics to meet with Yes Securities on June 26, 2025

Source |07:56 23 Jun 25

agm-egm corporate actions

Krsnaa Diagnostics Limited will be meeting with Investors/Analysts.
The meeting is scheduled for June 26, 2025, in Pune.
The meeting will be with Yes Securities and will be a physical one-on-one interaction.
Discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.

KRSNAA

Krsnaa Diagnostics to meet with Aditya Birla Money on June 16, 2025

Source |09:18 14 Jun 25

agm-egm regulatory filings

Krsnaa Diagnostics Limited will be meeting with investors/analysts on June 16, 2025 in Mumbai.
The meeting is a one-on-one interaction with Aditya Birla Money.
The interaction will be physical and is scheduled for 14:00 Hrs (IST).
Discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.

KRSNAA

Krsnaa Diagnostics to Meet Motilal Oswal Securities on May 21, 2025

Source |07:40 20 May 25

press release

Krsnaa Diagnostics Limited (KRSNAA) has informed the exchanges that company officials will be meeting with Motilal Oswal Securities.

The meeting is scheduled for May 21, 2025.
It will be a physical one-on-one interaction.
The meeting will take place in Mumbai at 13:30 Hrs. (IST).
Discussions will be based on publicly available information.
No unpublished price sensitive information (UPSI) is intended to be discussed.

KRSNAA

Krsnaa Diagnostics FY25 Earnings: 16% Revenue Growth, 34% EBITDA Increase

Source |15:12 19 May 25

results strategic partnerships new orders

Krsnaa Diagnostics Limited announced its Q4 and FY25 results in an earnings conference call on May 13, 2025.
FY25 revenue grew by 16% to ₹71.72 crore, driven by increased awareness, patient volumes, and pricing efficiency.
EBITDA rose by 34% to ₹19.58 crore, with margins expanding by 370 basis points to 27%, reflecting strong operating leverage.
Net profit grew by 37% to ₹7.76 crore, highlighting a disciplined approach to cost and productivity.
The company served over 19 million patients and conducted over 61 million tests during the year.
Revenue growth was lower than the aspired 20-25% due to delays in site handovers for Maharashtra CT MRI projects and the early conclusion of the BMC project.
The company chose not to pursue the new BMC tender due to revised conditions and budgetary caps.
The company is focusing on capital discipline and quality of revenue, rationalizing exposure in certain regions with disproportionate receivables.
The retail strategy has gained momentum, with a 4x increase in touchpoints across 4 states.
The company is executing on five major priorities: expanding PPP leadership, growing integrated diagnostic offerings, driving sustainable profitability, accelerating retail footprint, and leading on quality with accreditations.
Krsnaa is optimistic about the future, focusing on building a healthcare platform for the next decade.
Mitesh Dave, Group CEO, highlighted the strong growth potential in the retail diagnostics business under the RPL brand, driven by increasing demand for home collection services, preventive diagnostics, and digital solutions.
RPL is scaling its retail footprint across Maharashtra, Punjab, Assam, and Odisha, leveraging the company's PPP infrastructure.
Pawan Daga, CFO, mentioned that Q4 FY25 revenue stood at ₹18.61 crore, a 12% year-on-year increase.
EBITDA for Q4 FY25 stood at ₹5.42 crore, a 23% year-on-year increase with a margin of 29%.
The board has recommended a dividend of ₹2.75 per share.
The company holds gross debt of ₹16.55 crore and cash and cash equivalents of ₹17.60 crore.
Receivables stand at 128 days, primarily due to transitional delays in Himachal Pradesh and Karnataka. The company expects systematic improvement in payments with the rollout of digitized payment infrastructure.
Yash Mutha (MD) mentioned that the company is carefully showing the realistic numbers and the market is not slowing down. The government wishes to have more than 2,000 radiology centers and the company is just a few hundred. The company is very selective and calibrated in terms of showing realistic numbers.
When asked about the revenue potential from the retail venture by FY27, Mitesh Dave (Group CEO) said that it is a little too early to give the outlook because the entire business and structures and systems are getting into place. But with the initial one year centers or the touch points that have been formed up, the company has laid down across India in the 4 states, these are pretty promising.
The interest component with Medikabazaar and United Imaging partnership is 7% annually.

KRSNAA

Krsnaa Diagnostics to meet with investors/analysts on 28 May 2025

Source |08:22 15 May 25

agm-egm regulatory filings

Krsnaa Diagnostics Limited will be meeting with investors/analysts at the B & K Annual Investor Conference in Mumbai on 28 May 2025.
The meeting will be a group meeting conducted physically, starting from 10:00 Hrs (IST) onwards.
Discussions will be based on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.
The schedule is subject to change due to exigencies on the part of the Analyst/Institutional Investor or the Company.